About Company

Rxilient team members celebrating a successful collaboration

who we are

Rxilient offers full value chain capabilities, from registration and commercialization to manufacturing and supply chain management. Partnering with innovators and multinationals to develop and commercialize leading medicines.


We transform lives through connecting global innovation to local patients.


Become the leading pharma company in emerging markets, recognised for offering high-quality, accessible and affordable therapies to patients.

Customer Value Proposition

With its unique local presence and expertise, Rxilient enables the development, registration, supply and commercialization of global innovative products in complex emerging markets, benefiting patients in those regions.

Core Values


  • Customer Focused
  • Ownership
  • Ambitious
  • Integrity
  • Result Driven

our history

The journey of Rxilient began in 2021 with the establishment of three entities in Singapore, committed to healthcare innovation and market alignment.

  • 2021

    Inception of Rxilient Singapore.

  • 2022

    Rxilient’s geographic expansion included the setup of operations in Shanghai, Malaysia, and Indonesia.

  • 2023
    • Continued global reach with new offices in the Philippines, Thailand, and Vietnam.
    • Strategic launch of Excellmab, a joint venture between Rxilient Biotech and Junshi Biosciences, to develop and commercialize Toripalimab in Southeast Asia.
  • 2024

    Rxilient’s expansion into Taiwan and Dubai through new office establishments.

reach us today

Your gateway to rxilient,
Get in touch with us